Skip to main content
Fig. 6 | Journal of Nanobiotechnology

Fig. 6

From: Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy

Fig. 6

EVs-Cas9-29b therapy attenuate denervation induced muscle atrophy in vivo. a Schematic diagram of the experimental design process. b qRT-PCR analysis for the expression of miR-29b in gastrocnemius muscle of mice injected with EVs-Cas9-29b in Den-induced muscle atrophy (n = 10,10,8,8). c Western blot analysis of the Cas9 protein in gastrocnemius muscle of mice injected with EVs-Cas9-29b in Den-induced muscle atrophy (n = 6). d Gastrocnemius muscle morphology, weight and Gastrocnemius weight/body Weight ratio of mice injected with EVs-Cas9-29b in Den-induced muscle atrophy (n = 10,10,8,8). e qRT-PCR analysis of Atrogin-1 and MuRF-1 expression in gastrocnemius muscle of mice injected with EVs-Cas9-29b in Den-induced muscle atrophy (n = 10,10,8,8). f–g HE staining and WGA staining for myofiber of mice injected with EVs-Cas9-29b in Den-induced muscle atrophy (HE:n = 9,10,8,8; scale bar:100 μm; WGA: n = 10,10,8,8; scale bar:100 μm). h. Western blot analysis for AKT/FOXO3A/mTOR pathway (AKT, FOXO3A, mTOR, P70S6K, 4EBP1) in gastrocnemius muscle of mice injected with EVs-Cas9-29b in Den-induced muscle atrophy (n = 6 per group). Data were presented as mean ± SD. Statistical significance was determined by Two-way ANOVA with Tukey test (bh). *P < 0.05; **P < 0.01 and ***P < 0.001

Back to article page